Every Form 4 that LAVA Therapeutics N.V. (LVTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LVTX filings page.
LAVA Therapeutics N.V. (LVTX) reported an insider equity transaction by its Chief Financial Officer. On 11/13/2025, the CFO disposed of 65,000 common shares and had 124,700 share options cancelled. Both actions were carried out under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation.
Each common share was exchanged for $1.04 in cash plus one non-transferable contingent value right (CVR). Each in-the-money option was cancelled in return for cash, based on the excess of $1.04 over the option’s exercise price, and one CVR per underlying share, net of applicable taxes and deductions.
LAVA Therapeutics N.V. reported that a director cancelled an option to buy 33,390 common shares with an exercise price of $0.93 per share on 11/13/2025. The option had been scheduled to expire on 02/12/2035. Under a Purchase Agreement between the company and XOMA Royalty Corporation, the cancellation consideration consists of cash equal to the excess of $1.04 over the per-share exercise price multiplied by the number of shares underlying the option, plus one contingent value right for each in-the-money share. Following this transaction, the reporting person held 0 derivative securities of this type.
LAVA Therapeutics N.V. (LVTX) reported an insider equity change on Form 4. A director cancelled a stock option covering 33,390 common shares with a per share exercise price of $0.93 on 11/13/2025. The option had been exercisable until 02/12/2035. According to a purchase agreement dated 08/03/2025 between the company and XOMA Royalty Corporation, the option was cancelled in exchange for cash and contingent value rights (CVRs). The cash component equals the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR for each share underlying the in-the-money option.
LAVA Therapeutics N.V. (LVTX) reported a Form 4 showing that a director’s stock option was fully cancelled in a structured transaction. On 11/13/2025, a share option covering 33,390 common shares with a per share exercise price of $0.93 was disposed of as a derivative security.
The option was cancelled under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation. In exchange, the reporting person received cash and contingent value rights (CVRs) equal to the excess of $1.04 over the option exercise price, multiplied by the number of underlying shares, plus one CVR for each in-the-money underlying share. Following this transaction, the reporting person reported 0 derivative securities beneficially owned.
LAVA Therapeutics N.V. (LVTX) disclosed on a Form 4 that one of its directors reported the cancellation of a stock option on 11/13/2025. The derivative position was a right to buy common shares at an exercise price of $0.93 per share covering 33,390 underlying common shares, and following the transaction the director held zero of these derivative securities directly.
The filing explains that this option was cancelled under an August 3, 2025 Purchase Agreement between the issuer and XOMA Royalty Corporation. In exchange, the option holder became entitled to cash and contingent value rights, calculated as the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one contingent value right for each in-the-money option share.
A director of LAVA Therapeutics N.V. (LVTX) reported a change in holdings on Form 4. On 11/13/2025, a stock option covering 33,390 common shares with a per share exercise price of $0.93 was cancelled. The option was cancelled under a Purchase Agreement between the issuer and XOMA Royalty Corporation. In exchange, the holder became entitled to cash and contingent value rights, calculated as the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR for each in-the-money underlying share.
LAVA Therapeutics N.V. director reported a disposition of common shares and related options tied to a Purchase Agreement with XOMA Royalty Corporation. The director disposed of 10,000 common shares on 11/13/2025 and no common shares remained beneficially owned afterward. A stock option covering 33,390 common shares with a per share exercise price of $0.93 was cancelled on the same date. In exchange, the reporting person received $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share
LAVA Therapeutics N.V. director reported changes in holdings tied to a previously signed Purchase Agreement with XOMA Royalty Corporation. On 11/13/2025, the director disposed of 30,000 common shares, receiving $1.04 in cash per share plus one contingent value right (CVR) for each share. On the same date, a stock option covering 33,390 common shares with a $0.93 exercise price was cancelled under the same agreement in exchange for cash and CVRs, calculated as the excess of $1.04 over the option exercise price multiplied by the number of underlying shares, plus one CVR per in-the-money share.
LAVA Therapeutics N.V. (LVTX) reported an insider transaction by its Chief Executive Officer and director on 11/13/2025. The reporting person disposed of 5,000 common shares and had 335,100 share options cancelled in connection with a previously signed Purchase Agreement with XOMA Royalty Corporation.
Each common share was exchanged for $1.04 in cash per share plus one non-transferable contingent value right (CVR). Each in-the-money option entitled the holder to cash and CVRs equal to the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR per underlying share, after applicable taxes and deductions. Following these transactions, the reporting person no longer held the reported shares or options.